Background Platinum-doublet, first-line treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) is limited to 4–6 cycles. An alternative strategy used to …

Background First-line maintenance erlotinib in patients with locally advanced or metastatic
nonsmall cell lung cancer (NSCLC) has demonstrated significant overall survival and …

Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line
maintenance treatment of patients with locally advanced or metastatic non-small-cell lung …

BACKGROUND: Various drug therapies are available for treatment of refractory stage IIIB/IV
non-small cell lung cancer (NSCLC), but their comparative economic value is unclear …

Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …

7664 Background: Multiple treatment strategies are now available for stage IIIB/IV non-small
cell lung cancer (NSCLC) after failure of 1st line treatment, but their relative economic and …

Abstract The UK National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of erlotinib (Roche) to submit evidence for the clinical and cost effectiveness of …

This study was designed to assess the cost-effectiveness of erlotinib compared with
docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) …

Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …

Introduction: Erlotinib was recently approved in British Columbia (BC) as a second-line
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …